Integrated cervical cancer screening in Mayuge district Uganda (ASPIRE Mayuge)

Not Applicable

Completed

• Conditions: Cervical cancer and cervical pre-cancer; Cancer

• Registration Number: ISRCTN12767014
• Lead Sponsor: niversity of British Columbia

Brief Summary

2020 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/32005202 protocol (added 03/02/2020) 2022 Preprint results in https://dx.doi.org/10.2139/ssrn.4068261 (added 30/06/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37037880/ (added 11/04/2023) 2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/36408923/ Participant experiences (added 06/06/2024)

Detailed Description

Not available

Study Timeline

• Study Start: 2019-05-17
• Study Completion: 2021-12-31
• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 2019

Inclusion Criteria

1. Women with no previous history of hysterectomy or invasive cervical cancer
2. Aged 25-49 years old
3. Not previously been screened and treated for cervical cancer
4. Provided written informed consent

Exclusion Criteria

Do not fulfil inclusion criteria.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The difference in the rate of follow-up care for women who test positive for HR-HPV types out of all women screened in each trial arm. This will include the total number of women who completed self-collection cervical cancer screening at baseline and the proportion of women who complete VIA follow-up and treatment after testing positive for high-risk HPV type at endline (two weeks).